Bortezomib Plus Melphalan--Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan--Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use.
Bortezomib Plus Melphalan--Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan--Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use.
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Δεν υπάρχει περίληψη
Έτος δημοσίευσης:
2009
Συγγραφείς:
Mateos, Maria-Victoria Richardson, Paul G Schlag, Rudolf Khuageva, Nuriet K Dimopoulos, Meletios A Shpilberg, Ofer Kropff, Martin Spicka, Ivan Petrucci, Maria Teresa Palumbo, Antonio others
